Tag: Trodelvy

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

Gilead Accelerate Its Oncology ADC Pipeline by Acquiring Tubulis for $5B

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

A first patients has been dosed in the WIN-B study (NCT06612203)*, a Phase 1b/2, multi-center investigator-initiated trial evaluating the safety and preliminary efficacy of...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992 (also known as BSI-992), to conduct a...

During the annual ESMO 2023 Congress, organized by the European Society for Medical Oncology, held October 20 - 24, 2023 in Madrid, Spain, antibody-drug conjugates or ADCs took center stage, with presentations demonstrating the potential these ADCs show in the rapidly changing treatment landscape for various cancers.

In early February this year, the U.S. Food and Drug Administration (FDA) approved  sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) for the treatment of adult patients with...

Gilead Sciences and Strata Oncology have signed an agreement in which Gilead has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™; NCT05097599) study by providing sacituzumab govitecan-hziy (Trodelvy®) for eligible patients with cancer.